With a one year PEG ratio of 0.64, Arcturus Therapeutics Holdings Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than only 6.04% of US stocks.
ARCT's price/sales ratio is 160.52; that's higher than the P/S ratio of 97.24% of US stocks.
Revenue growth over the past 12 months for Arcturus Therapeutics Holdings Inc comes in at -46.19%, a number that bests merely 6.23% of the US stocks we're tracking.
Stocks with similar financial metrics, market capitalization, and price volatility to Arcturus Therapeutics Holdings Inc are EVGN, CLDX, KALV, SYBX, and FULC.
ARCT's SEC filings can be seen here. And to visit Arcturus Therapeutics Holdings Inc's official web site, go to www.arcturusrx.com.
Shares of Arcturus Therapeutics (NASDAQ: ARCT) were skyrocketing 40.9% higher as of 3:10 p.m. EST on Thursday. The huge gain came after Wells Fargo analyst Jim Birchenough initiated coverage on the stock with an overweight rating. Arcturus' shares plunged in December after the company announced updated results from a phase 2 study of COVID-19 vaccine candidate ARCT-021 that disappointed investors.